Toll-like receptor 9

<p>This section provides any useful information about the protein, mostly biological knowledge.<p><a href='/help/function_section' target='_top'>More...</a></p>Functionⁱ

Sites

<p>The <a href="http://www.geneontology.org/">Gene Ontology (GO)</a> project provides a set of hierarchical controlled vocabulary split into 3 categories:<p><a href='/help/gene_ontology' target='_top'>More...</a></p>GO - Molecular functionⁱ

• 1-phosphatidylinositol-3-kinase activity Source: Reactome
• interleukin-1 receptor binding Source: UniProtKB <p>Inferred from Physical Interaction</p> <p>Covers physical interactions between the gene product of interest and another molecule (or ion, or complex).</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#ipi">GO evidence code guide</a></p> Inferred from physical interactionⁱ
  • "SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling."
    Wald D., Qin J., Zhao Z., Qian Y., Naramura M., Tian L., Towne J., Sims J.E., Stark G.R., Li X.
    Nat. Immunol. 4:920-927(2003) [PubMed] [Europe PMC] [Abstract]
• protein homodimerization activity Source: UniProtKB
• signaling pattern recognition receptor activity Source: GO_Central <p>Inferred from Biological aspect of Ancestor</p> <p>A type of phylogenetic evidence whereby an aspect of a descendent is inferred through the characterization of an aspect of a ancestral gene.</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#iba">GO evidence code guide</a></p> Inferred from biological aspect of ancestorⁱ
  • "Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium."
    Gaudet P., Livstone M.S., Lewis S.E., Thomas P.D.
    Brief. Bioinformatics 12:449-462(2011) [PubMed] [Europe PMC] [Abstract]
• siRNA binding Source: UniProtKB <p>Inferred from Mutant Phenotype</p> <p>Describes annotations that are concluded from looking at variations or changes in a gene product such as mutations or abnormal levels and includes techniques such as knockouts, overexpression, anti-sense experiments and use of specific protein inhibitors.</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#imp">GO evidence code guide</a></p> Inferred from mutant phenotypeⁱ
  • "Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7."
    Hornung V., Guenthner-Biller M., Bourquin C., Ablasser A., Schlee M., Uematsu S., Noronha A., Manoharan M., Akira S., de Fougerolles A., Endres S., Hartmann G.
    Nat. Med. 11:263-270(2005) [PubMed] [Europe PMC] [Abstract]
• transmembrane signaling receptor activity Source: InterPro
• unmethylated CpG binding Source: UniProtKB

GO - Biological processⁱ

• defense response to bacterium Source: UniProtKB <p>Non-traceable Author Statement</p> <p>Used for statements in the abstract, introduction or discussion of a paper that cannot be traced back to another publication.</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#nas">GO evidence code guide</a></p> Non-traceable author statementⁱ
  • Ref.3

    "A Toll-like receptor recognizes bacterial DNA."
    Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., Akira S.
    Nature 408:740-745(2000) [PubMed] [Europe PMC] [Abstract]

    Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
• defense response to Gram-negative bacterium Source: UniProtKBInferred from mutant phenotypeⁱ
  • "Vigorous response of human innate functioning IgM memory B cells upon infection by Neisseria gonorrhoeae."
    So N.S., Ostrowski M.A., Gray-Owen S.D.
    J. Immunol. 188:4008-4022(2012) [PubMed] [Europe PMC] [Abstract]
• defense response to virus Source: GO_CentralInferred from biological aspect of ancestorⁱ
  • "Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium."
    Gaudet P., Livstone M.S., Lewis S.E., Thomas P.D.
    Brief. Bioinformatics 12:449-462(2011) [PubMed] [Europe PMC] [Abstract]
• I-kappaB kinase/NF-kappaB signaling Source: GO_CentralInferred from biological aspect of ancestorⁱ
  • "Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium."
    Gaudet P., Livstone M.S., Lewis S.E., Thomas P.D.
    Brief. Bioinformatics 12:449-462(2011) [PubMed] [Europe PMC] [Abstract]
• I-kappaB phosphorylation Source: BHF-UCL <p>Inferred from Direct Assay</p> <p>Used to indicate a direct assay for the function, process or component indicated by the GO term.</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#ida">GO evidence code guide</a></p> Inferred from direct assayⁱ
  • "Cultured human melanocytes express functional toll-like receptors 2-4, 7 and 9."
    Yu N., Zhang S., Zuo F., Kang K., Guan M., Xiang L.
    J. Dermatol. Sci. 56:113-120(2009) [PubMed] [Europe PMC] [Abstract]
• immune response Source: GO_CentralInferred from biological aspect of ancestorⁱ
  • "Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium."
    Gaudet P., Livstone M.S., Lewis S.E., Thomas P.D.
    Brief. Bioinformatics 12:449-462(2011) [PubMed] [Europe PMC] [Abstract]
• inflammatory response Source: UniProtKB-KW
• innate immune response Source: BHF-UCL <p>Traceable Author Statement</p> <p>Used for information from review articles where the original experiments are traceable through that article and also for information from text books or dictionaries.</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#tas">GO evidence code guide</a></p> Traceable author statementⁱ
  • "Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs."
    Olson J.K., Miller S.D.
    J. Immunol. 173:3916-3924(2004) [PubMed] [Europe PMC] [Abstract]
• maintenance of gastrointestinal epithelium Source: BHF-UCL
• MyD88-dependent toll-like receptor signaling pathway Source: InterPro
• negative regulation of calcium-transporting ATPase activity Source: CACAOInferred from direct assayⁱ
  • "Toll-like receptor 9 protects non-immune cells from stress by modulating mitochondrial ATP synthesis through the inhibition of SERCA2."
    Shintani Y., Drexler H.C., Kioka H., Terracciano C.M., Coppen S.R., Imamura H., Akao M., Nakai J., Wheeler A.P., Higo S., Nakayama H., Takashima S., Yashiro K., Suzuki K.
    EMBO Rep. 15:438-445(2014) [PubMed] [Europe PMC] [Abstract]
• negative regulation of interleukin-6 production Source: BHF-UCL
• negative regulation of interleukin-8 production Source: BHF-UCLInferred from direct assayⁱ
  • "Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells."
    Lee J., Mo J.H., Katakura K., Alkalay I., Rucker A.N., Liu Y.T., Lee H.K., Shen C., Cojocaru G., Shenouda S., Kagnoff M., Eckmann L., Ben-Neriah Y., Raz E.
    Nat. Cell Biol. 8:1327-1336(2006) [PubMed] [Europe PMC] [Abstract]
• negative regulation of NF-kappaB transcription factor activity Source: BHF-UCLInferred from direct assayⁱ
  • "Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells."
    Lee J., Mo J.H., Katakura K., Alkalay I., Rucker A.N., Liu Y.T., Lee H.K., Shen C., Cojocaru G., Shenouda S., Kagnoff M., Eckmann L., Ben-Neriah Y., Raz E.
    Nat. Cell Biol. 8:1327-1336(2006) [PubMed] [Europe PMC] [Abstract]
• negative regulation of toll-like receptor signaling pathway Source: BHF-UCLInferred from direct assayⁱ
  • "Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells."
    Lee J., Mo J.H., Katakura K., Alkalay I., Rucker A.N., Liu Y.T., Lee H.K., Shen C., Cojocaru G., Shenouda S., Kagnoff M., Eckmann L., Ben-Neriah Y., Raz E.
    Nat. Cell Biol. 8:1327-1336(2006) [PubMed] [Europe PMC] [Abstract]
• positive regulation of B cell activation Source: UniProtKBInferred from direct assayⁱ
  • Ref.13

    "FCRL3 promotes TLR9-induced B-cell activation and suppresses plasma cell differentiation."
    Li F.J., Schreeder D.M., Li R., Wu J., Davis R.S.
    Eur. J. Immunol. 43:2980-2992(2013) [PubMed] [Europe PMC] [Abstract]

    Cited for: FUNCTION.
• positive regulation of B cell proliferation Source: UniProtKBInferred from direct assayⁱ
  • Ref.13

    "FCRL3 promotes TLR9-induced B-cell activation and suppresses plasma cell differentiation."
    Li F.J., Schreeder D.M., Li R., Wu J., Davis R.S.
    Eur. J. Immunol. 43:2980-2992(2013) [PubMed] [Europe PMC] [Abstract]

    Cited for: FUNCTION.
• positive regulation of chemokine production Source: BHF-UCLInferred from direct assayⁱ
  • "Cultured human melanocytes express functional toll-like receptors 2-4, 7 and 9."
    Yu N., Zhang S., Zuo F., Kang K., Guan M., Xiang L.
    J. Dermatol. Sci. 56:113-120(2009) [PubMed] [Europe PMC] [Abstract]
• positive regulation of gene expression Source: CACAOInferred from direct assayⁱ
  • "TLR9 and RIG-I signaling in human endocervical epithelial cells modulates inflammatory responses of macrophages and dendritic cells in vitro."
    Sathe A., Reddy K.V.
    PLoS ONE 9:e83882-e83882(2014) [PubMed] [Europe PMC] [Abstract]
• positive regulation of granulocyte macrophage colony-stimulating factor production Source: CACAOInferred from direct assayⁱ
  • "TLR9 and RIG-I signaling in human endocervical epithelial cells modulates inflammatory responses of macrophages and dendritic cells in vitro."
    Sathe A., Reddy K.V.
    PLoS ONE 9:e83882-e83882(2014) [PubMed] [Europe PMC] [Abstract]
• positive regulation of I-kappaB kinase/NF-kappaB signaling Source: BHF-UCLInferred from direct assayⁱ
  • "Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells."
    Lee J., Mo J.H., Katakura K., Alkalay I., Rucker A.N., Liu Y.T., Lee H.K., Shen C., Cojocaru G., Shenouda S., Kagnoff M., Eckmann L., Ben-Neriah Y., Raz E.
    Nat. Cell Biol. 8:1327-1336(2006) [PubMed] [Europe PMC] [Abstract]
• positive regulation of immunoglobulin production Source: UniProtKBInferred from direct assayⁱ
  • Ref.13

    "FCRL3 promotes TLR9-induced B-cell activation and suppresses plasma cell differentiation."
    Li F.J., Schreeder D.M., Li R., Wu J., Davis R.S.
    Eur. J. Immunol. 43:2980-2992(2013) [PubMed] [Europe PMC] [Abstract]

    Cited for: FUNCTION.
• positive regulation of inflammatory response Source: BHF-UCL <p>Inferred by Curator</p> <p>Used for cases where an annotation is not supported by any evidence but can be reasonably inferred by a curator from other GO annotations for which evidence <br />is available.</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#ic">GO evidence code guide</a></p> Inferred by curatorⁱ
  • "Cultured human melanocytes express functional toll-like receptors 2-4, 7 and 9."
    Yu N., Zhang S., Zuo F., Kang K., Guan M., Xiang L.
    J. Dermatol. Sci. 56:113-120(2009) [PubMed] [Europe PMC] [Abstract]
• positive regulation of interferon-alpha biosynthetic process Source: UniProtKBInferred from direct assayⁱ
  • "Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha/beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses."
    Yang K., Puel A., Zhang S., Eidenschenk C., Ku C.L., Casrouge A., Picard C., von Bernuth H., Senechal B., Plancoulaine S., Al-Hajjar S., Al-Ghonaium A., Marodi L., Davidson D., Speert D., Roifman C., Garty B.Z., Ozinsky A.

    , Barrat F.J., Coffman R.L., Miller R.L., Li X., Lebon P., Rodriguez-Gallego C., Chapel H., Geissmann F., Jouanguy E., Casanova J.L.
    Immunity 23:465-478(2005) [PubMed] [Europe PMC] [Abstract]
• positive regulation of interferon-beta biosynthetic process Source: UniProtKBInferred from direct assayⁱ
  • "Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha/beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses."
    Yang K., Puel A., Zhang S., Eidenschenk C., Ku C.L., Casrouge A., Picard C., von Bernuth H., Senechal B., Plancoulaine S., Al-Hajjar S., Al-Ghonaium A., Marodi L., Davidson D., Speert D., Roifman C., Garty B.Z., Ozinsky A.

    , Barrat F.J., Coffman R.L., Miller R.L., Li X., Lebon P., Rodriguez-Gallego C., Chapel H., Geissmann F., Jouanguy E., Casanova J.L.
    Immunity 23:465-478(2005) [PubMed] [Europe PMC] [Abstract]
• positive regulation of interferon-beta production Source: BHF-UCL
• positive regulation of interferon-gamma biosynthetic process Source: UniProtKBInferred from direct assayⁱ
  • "Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha/beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses."
    Yang K., Puel A., Zhang S., Eidenschenk C., Ku C.L., Casrouge A., Picard C., von Bernuth H., Senechal B., Plancoulaine S., Al-Hajjar S., Al-Ghonaium A., Marodi L., Davidson D., Speert D., Roifman C., Garty B.Z., Ozinsky A.

    , Barrat F.J., Coffman R.L., Miller R.L., Li X., Lebon P., Rodriguez-Gallego C., Chapel H., Geissmann F., Jouanguy E., Casanova J.L.
    Immunity 23:465-478(2005) [PubMed] [Europe PMC] [Abstract]
• positive regulation of interleukin-10 production Source: BHF-UCL
• positive regulation of interleukin-12 production Source: BHF-UCL
• positive regulation of interleukin-18 production Source: BHF-UCL
• positive regulation of interleukin-6 production Source: BHF-UCLInferred from direct assayⁱ
  • "Cultured human melanocytes express functional toll-like receptors 2-4, 7 and 9."
    Yu N., Zhang S., Zuo F., Kang K., Guan M., Xiang L.
    J. Dermatol. Sci. 56:113-120(2009) [PubMed] [Europe PMC] [Abstract]
• positive regulation of interleukin-8 biosynthetic process Source: GO_CentralInferred from biological aspect of ancestorⁱ
  • "Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium."
    Gaudet P., Livstone M.S., Lewis S.E., Thomas P.D.
    Brief. Bioinformatics 12:449-462(2011) [PubMed] [Europe PMC] [Abstract]
• positive regulation of interleukin-8 production Source: BHF-UCLInferred from direct assayⁱ
  • "Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells."
    Lee J., Mo J.H., Katakura K., Alkalay I., Rucker A.N., Liu Y.T., Lee H.K., Shen C., Cojocaru G., Shenouda S., Kagnoff M., Eckmann L., Ben-Neriah Y., Raz E.
    Nat. Cell Biol. 8:1327-1336(2006) [PubMed] [Europe PMC] [Abstract]
  • "Cultured human melanocytes express functional toll-like receptors 2-4, 7 and 9."
    Yu N., Zhang S., Zuo F., Kang K., Guan M., Xiang L.
    J. Dermatol. Sci. 56:113-120(2009) [PubMed] [Europe PMC] [Abstract]
• positive regulation of JNK cascade Source: BHF-UCLInferred by curatorⁱ
  • "Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells."
    Lee J., Mo J.H., Katakura K., Alkalay I., Rucker A.N., Liu Y.T., Lee H.K., Shen C., Cojocaru G., Shenouda S., Kagnoff M., Eckmann L., Ben-Neriah Y., Raz E.
    Nat. Cell Biol. 8:1327-1336(2006) [PubMed] [Europe PMC] [Abstract]
• positive regulation of JUN kinase activity Source: BHF-UCLInferred from direct assayⁱ
  • "Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells."
    Lee J., Mo J.H., Katakura K., Alkalay I., Rucker A.N., Liu Y.T., Lee H.K., Shen C., Cojocaru G., Shenouda S., Kagnoff M., Eckmann L., Ben-Neriah Y., Raz E.
    Nat. Cell Biol. 8:1327-1336(2006) [PubMed] [Europe PMC] [Abstract]
• positive regulation of MAPK cascade Source: UniProtKBInferred from direct assayⁱ
  • Ref.13

    "FCRL3 promotes TLR9-induced B-cell activation and suppresses plasma cell differentiation."
    Li F.J., Schreeder D.M., Li R., Wu J., Davis R.S.
    Eur. J. Immunol. 43:2980-2992(2013) [PubMed] [Europe PMC] [Abstract]

    Cited for: FUNCTION.
• positive regulation of NF-kappaB transcription factor activity Source: BHF-UCLInferred from direct assayⁱ
  • "Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells."
    Lee J., Mo J.H., Katakura K., Alkalay I., Rucker A.N., Liu Y.T., Lee H.K., Shen C., Cojocaru G., Shenouda S., Kagnoff M., Eckmann L., Ben-Neriah Y., Raz E.
    Nat. Cell Biol. 8:1327-1336(2006) [PubMed] [Europe PMC] [Abstract]
• positive regulation of NIK/NF-kappaB signaling Source: BHF-UCLInferred from direct assayⁱ
  • "Cultured human melanocytes express functional toll-like receptors 2-4, 7 and 9."
    Yu N., Zhang S., Zuo F., Kang K., Guan M., Xiang L.
    J. Dermatol. Sci. 56:113-120(2009) [PubMed] [Europe PMC] [Abstract]
• positive regulation of nitric-oxide synthase biosynthetic process Source: BHF-UCL
• positive regulation of toll-like receptor signaling pathway Source: BHF-UCLInferred from direct assayⁱ
  • "Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells."
    Lee J., Mo J.H., Katakura K., Alkalay I., Rucker A.N., Liu Y.T., Lee H.K., Shen C., Cojocaru G., Shenouda S., Kagnoff M., Eckmann L., Ben-Neriah Y., Raz E.
    Nat. Cell Biol. 8:1327-1336(2006) [PubMed] [Europe PMC] [Abstract]
• positive regulation of transcription by RNA polymerase II Source: BHF-UCL
• positive regulation of tumor necrosis factor production Source: BHF-UCL
• regulation of B cell differentiation Source: UniProtKBInferred from direct assayⁱ
  • Ref.13

    "FCRL3 promotes TLR9-induced B-cell activation and suppresses plasma cell differentiation."
    Li F.J., Schreeder D.M., Li R., Wu J., Davis R.S.
    Eur. J. Immunol. 43:2980-2992(2013) [PubMed] [Europe PMC] [Abstract]

    Cited for: FUNCTION.
• regulation of cytokine secretion Source: InterPro
• regulation of toll-like receptor 9 signaling pathway Source: UniProtKBInferred from direct assayⁱ
  • Ref.13

    "FCRL3 promotes TLR9-induced B-cell activation and suppresses plasma cell differentiation."
    Li F.J., Schreeder D.M., Li R., Wu J., Davis R.S.
    Eur. J. Immunol. 43:2980-2992(2013) [PubMed] [Europe PMC] [Abstract]

    Cited for: FUNCTION.
• response to molecule of bacterial origin Source: BHF-UCLTraceable author statementⁱ
  • "Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs."
    Olson J.K., Miller S.D.
    J. Immunol. 173:3916-3924(2004) [PubMed] [Europe PMC] [Abstract]
• toll-like receptor 9 signaling pathway Source: Reactome
• toll-like receptor signaling pathway Source: GO_CentralInferred from biological aspect of ancestorⁱ
  • "Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium."
    Gaudet P., Livstone M.S., Lewis S.E., Thomas P.D.
    Brief. Bioinformatics 12:449-462(2011) [PubMed] [Europe PMC] [Abstract]
• tumor necrosis factor production Source: CACAOInferred from direct assayⁱ
  • "TLR7/TLR8 Activation Restores Defective Cytokine Secretion by Myeloid Dendritic Cells but Not by Plasmacytoid Dendritic Cells in HIV-Infected Pregnant Women and Newborns."
    Cardoso E.C., Pereira N.Z., Mitsunari G.E., Oliveira L.M., Ruocco R.M., Francisco R.P., Zugaib M., da Silva Duarte A.J., Sato M.N.
    PLoS ONE 8:e67036-e67036(2013) [PubMed] [Europe PMC] [Abstract]

<p>UniProtKB Keywords constitute a <a href="http://www.uniprot.org/keywords">controlled vocabulary</a> with a hierarchical structure. Keywords summarise the content of a UniProtKB entry and facilitate the search for proteins of interest.<p><a href='/help/keywords' target='_top'>More...</a></p>Keywordsⁱ

Enzyme and pathway databases

<p>This section provides information about the protein and gene name(s) and synonym(s) and about the organism that is the source of the protein sequence.<p><a href='/help/names_and_taxonomy_section' target='_top'>More...</a></p>Names & Taxonomyⁱ

Organism-specific databases

<p>This section provides information on the location and the topology of the mature protein in the cell.<p><a href='/help/subcellular_location_section' target='_top'>More...</a></p>Subcellular locationⁱ

Topology

Keywords - Cellular componentⁱ

<p>This section provides information on the disease(s) and phenotype(s) associated with a protein.<p><a href='/help/pathology_and_biotech_section' target='_top'>More...</a></p>Pathology & Biotechⁱ

Organism-specific databases

Chemistry databases

Polymorphism and mutation databases

<p>This section describes post-translational modifications (PTMs) and/or processing events.<p><a href='/help/ptm_processing_section' target='_top'>More...</a></p>PTM / Processingⁱ

Molecule processing

Amino acid modifications

<p>This subsection of the <a href="http://www.uniprot.org/help/ptm_processing_section">PTM/processing</a> section describes post-translational modifications (PTMs). This subsection <strong>complements</strong> the information provided at the sequence level or describes modifications for which <strong>position-specific data is not yet available</strong>.<p><a href='/help/post-translational_modification' target='_top'>More...</a></p>Post-translational modificationⁱ

Keywords - PTMⁱ

Proteomic databases

PTM databases

<p>This section provides information on the expression of a gene at the mRNA or protein level in cells or in tissues of multicellular organisms.<p><a href='/help/expression_section' target='_top'>More...</a></p>Expressionⁱ

<p>This subsection of the ‘Expression’ section provides information on the expression of a gene at the mRNA or protein level in cells or in tissues of multicellular organisms. By default, the information is derived from experiments at the mRNA level, unless specified ‘at protein level’. <br></br>Examples: <a href="http://www.uniprot.org/uniprot/P92958#expression">P92958</a>, <a href="http://www.uniprot.org/uniprot/Q8TDN4#expression">Q8TDN4</a>, <a href="http://www.uniprot.org/uniprot/O14734#expression">O14734</a><p><a href='/help/tissue_specificity' target='_top'>More...</a></p>Tissue specificityⁱ

Gene expression databases

<p>This section provides information on the quaternary structure of a protein and on interaction(s) with other proteins or protein complexes.<p><a href='/help/interaction_section' target='_top'>More...</a></p>Interactionⁱ

<p>This subsection of the <a href="http://www.uniprot.org/help/interaction_section">'Interaction'</a> section provides information about the protein quaternary structure and interaction(s) with other proteins or protein complexes (with the exception of physiological receptor-ligand interactions which are annotated in the <a href="http://www.uniprot.org/help/function_section">'Function'</a> section).<p><a href='/help/subunit_structure' target='_top'>More...</a></p>Subunit structureⁱ

GO - Molecular functionⁱ

• interleukin-1 receptor binding Source: UniProtKBInferred from physical interactionⁱ
  • "SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling."
    Wald D., Qin J., Zhao Z., Qian Y., Naramura M., Tian L., Towne J., Sims J.E., Stark G.R., Li X.
    Nat. Immunol. 4:920-927(2003) [PubMed] [Europe PMC] [Abstract]
• protein homodimerization activity Source: UniProtKB

Protein-protein interaction databases

Chemistry databases

<p>This section provides information on the tertiary and secondary structure of a protein.<p><a href='/help/structure_section' target='_top'>More...</a></p>Structureⁱ

3D structure databases

<p>This section provides information on sequence similarities with other proteins and the domain(s) present in a protein.<p><a href='/help/family_and_domains_section' target='_top'>More...</a></p>Family & Domainsⁱ

Domains and Repeats

Region

<p>This subsection of the ‘Family and domains’ section provides information about the sequence similarity with other proteins.<p><a href='/help/sequence_similarities' target='_top'>More...</a></p>Sequence similaritiesⁱ

Keywords - Domainⁱ

Phylogenomic databases

Family and domain databases

<p>This section displays by default the canonical protein sequence and upon request all isoforms described in the entry. It also includes information pertinent to the sequence(s), including <a href="http://www.uniprot.org/help/sequence_length">length</a> and <a href="http://www.uniprot.org/help/sequences">molecular weight</a>.<p><a href='/help/sequences_section' target='_top'>More...</a></p>Sequences (5)ⁱ

<p>This subsection of the <a href="http://www.uniprot.org/help/sequences_section">Sequence</a> section indicates if the <a href="http://www.uniprot.org/help/canonical_and_isoforms">canonical sequence</a> displayed by default in the entry is complete or not.<p><a href='/help/sequence_status' target='_top'>More...</a></p>Sequence statusⁱ: Complete.

<p>This subsection of the <a href="http://www.uniprot.org/help/sequences_section">Sequence</a> section indicates if the <a href="http://www.uniprot.org/help/canonical_and_isoforms">canonical sequence</a> displayed by default in the entry is in its mature form or if it represents the precursor.<p><a href='/help/sequence_processing' target='_top'>More...</a></p>Sequence processingⁱ: The displayed sequence is further processed into a mature form.

        10         20         30         40         50
MGFCRSALHP LSLLVQAIML AMTLALGTLP AFLPCELQPH GLVNCNWLFL 
        60         70         80         90        100
KSVPHFSMAA PRGNVTSLSL SSNRIHHLHD SDFAHLPSLR HLNLKWNCPP 
       110        120        130        140        150
VGLSPMHFPC HMTIEPSTFL AVPTLEELNL SYNNIMTVPA LPKSLISLSL 
       160        170        180        190        200
SHTNILMLDS ASLAGLHALR FLFMDGNCYY KNPCRQALEV APGALLGLGN 
       210        220        230        240        250
LTHLSLKYNN LTVVPRNLPS SLEYLLLSYN RIVKLAPEDL ANLTALRVLD 
       260        270        280        290        300
VGGNCRRCDH APNPCMECPR HFPQLHPDTF SHLSRLEGLV LKDSSLSWLN 
       310        320        330        340        350
ASWFRGLGNL RVLDLSENFL YKCITKTKAF QGLTQLRKLN LSFNYQKRVS 
       360        370        380        390        400
FAHLSLAPSF GSLVALKELD MHGIFFRSLD ETTLRPLARL PMLQTLRLQM 
       410        420        430        440        450
NFINQAQLGI FRAFPGLRYV DLSDNRISGA SELTATMGEA DGGEKVWLQP 
       460        470        480        490        500
GDLAPAPVDT PSSEDFRPNC STLNFTLDLS RNNLVTVQPE MFAQLSHLQC 
       510        520        530        540        550
LRLSHNCISQ AVNGSQFLPL TGLQVLDLSH NKLDLYHEHS FTELPRLEAL 
       560        570        580        590        600
DLSYNSQPFG MQGVGHNFSF VAHLRTLRHL SLAHNNIHSQ VSQQLCSTSL 
       610        620        630        640        650
RALDFSGNAL GHMWAEGDLY LHFFQGLSGL IWLDLSQNRL HTLLPQTLRN 
       660        670        680        690        700
LPKSLQVLRL RDNYLAFFKW WSLHFLPKLE VLDLAGNQLK ALTNGSLPAG 
       710        720        730        740        750
TRLRRLDVSC NSISFVAPGF FSKAKELREL NLSANALKTV DHSWFGPLAS 
       760        770        780        790        800
ALQILDVSAN PLHCACGAAF MDFLLEVQAA VPGLPSRVKC GSPGQLQGLS 
       810        820        830        840        850
IFAQDLRLCL DEALSWDCFA LSLLAVALGL GVPMLHHLCG WDLWYCFHLC 
       860        870        880        890        900
LAWLPWRGRQ SGRDEDALPY DAFVVFDKTQ SAVADWVYNE LRGQLEECRG 
       910        920        930        940        950
RWALRLCLEE RDWLPGKTLF ENLWASVYGS RKTLFVLAHT DRVSGLLRAS 
       960        970        980        990       1000
FLLAQQRLLE DRKDVVVLVI LSPDGRRSRY VRLRQRLCRQ SVLLWPHQPS 
      1010       1020       1030 
GQRSFWAQLG MALTRDNHHF YNRNFCQGPT AE                    

        10         20         30         40         50
MAAPRGNVTS LSLSSNRIHH LHDSDFAHLP SLRHLNLKWN CPPVGLSPMH 
        60         70         80         90        100
FPCHMTIEPS TFLAVPTLEE LNLSYNNIMT VPALPKSLIS LSLSHTNILM 
       110        120        130        140        150
LDSASLAGLH ALRFLFMDGN CYYKNPCRQA LEVAPGALLG LGNLTHLSLK 
       160        170        180        190        200
YNNLTVVPRN LPSSLEYLLL SYNRIVKLAP EDLANLTALR VLDVGGNCRR 
       210        220        230        240        250
CDHAPNPCME CPRHFPQLHP DTFSHLSRLE GLVLKDSSLS WLNASWFRGL 
       260        270        280        290        300
GNLRVLDLSE NFLYKCITKT KAFQGLTQLR KLNLSFNYQK RVSFAHLSLA 
       310        320        330        340        350
PSFGSLVALK ELDMHGIFFR SLDETTLRPL ARLPMLQTLR LQMNFINQAQ 
       360        370        380        390        400
LGIFRAFPGL RYVDLSDNRI SGASELTATM GEADGGEKVW LQPGDLAPAP 
       410        420        430        440        450
VDTPSSEDFR PNCSTLNFTL DLSRNNLVTV QPEMFAQLSH LQCLRLSHNC 
       460        470        480        490        500
ISQAVNGSQF LPLTGLQVLD LSHNKLDLYH EHSFTELPRL EALDLSYNSQ 
       510        520        530        540        550
PFGMQGVGHN FSFVAHLRTL RHLSLAHNNI HSQVSQQLCS TSLRALDFSG 
       560        570        580        590        600
NALGHMWAEG DLYLHFFQGL SGLIWLDLSQ NRLHTLLPQT LRNLPKSLQV 
       610        620        630        640        650
LRLRDNYLAF FKWWSLHFLP KLEVLDLAGN QLKALTNGSL PAGTRLRRLD 
       660        670        680        690        700
VSCNSISFVA PGFFSKAKEL RELNLSANAL KTVDHSWFGP LASALQILDV 
       710        720        730        740        750
SANPLHCACG AAFMDFLLEV QAAVPGLPSR VKCGSPGQLQ GLSIFAQDLR 
       760        770        780        790        800
LCLDEALSWD CFALSLLAVA LGLGVPMLHH LCGWDLWYCF HLCLAWLPWR 
       810        820        830        840        850
GRQSGRDEDA LPYDAFVVFD KTQSAVADWV YNELRGQLEE CRGRWALRLC 
       860        870        880        890        900
LEERDWLPGK TLFENLWASV YGSRKTLFVL AHTDRVSGLL RASFLLAQQR 
       910        920        930        940        950
LLEDRKDVVV LVILSPDGRR SRYVRLRQRL CRQSVLLWPH QPSGQRSFWA 
       960        970 
QLGMALTRDN HHFYNRNFCQ GPTAE                            

        10         20         30         40         50
MPMKWSGWRW SWGPATHTAL PPPQGFCRSA LHPLSLLVQA IMLAMTLALG 
        60         70         80         90        100
TLPAFLPCEL QPHGLVNCNW LFLKSVPHFS MAAPRGNVTS LSLSSNRIHH 
       110        120        130        140        150
LHDSDFAHLP SLRHLNLKWN CPPVGLSPMH FPCHMTIEPS TFLAVPTLEE 
       160        170        180        190        200
LNLSYNNIMT VPALPKSLIS LSLSHTNILM LDSASLAGLH ALRFLFMDGN 
       210        220        230        240        250
CYYKNPCRQA LEVAPGALLG LGNLTHLSLK YNNLTVVPRN LPSSLEYLLL 
       260        270        280        290        300
SYNRIVKLAP EDLANLTALR VLDVGGNCRR CDHAPNPCME CPRHFPQLHP 
       310        320        330        340        350
DTFSHLSRLE GLVLKDSSLS WLNASWFRGL GNLRVLDLSE NFLYKCITKT 
       360        370        380        390        400
KAFQGLTQLR KLNLSFNYQK RVSFAHLSLA PSFGSLVALK ELDMHGIFFR 
       410        420        430        440        450
SLDETTLRPL ARLPMLQTLR LQMNFINQAQ LGIFRAFPGL RYVDLSDNRI 
       460        470        480        490        500
SGASELTATM GEADGGEKVW LQPGDLAPAP VDTPSSEDFR PNCSTLNFTL 
       510        520        530        540        550
DLSRNNLVTV QPEMFAQLSH LQCLRLSHNC ISQAVNGSQF LPLTGLQVLD 
       560        570        580        590        600
LSHNKLDLYH EHSFTELPRL EALDLSYNSQ PFGMQGVGHN FSFVAHLRTL 
       610        620        630        640        650
RHLSLAHNNI HSQVSQQLCS TSLRALDFSG NALGHMWAEG DLYLHFFQGL 
       660        670        680        690        700
SGLIWLDLSQ NRLHTLLPQT LRNLPKSLQV LRLRDNYLAF FKWWSLHFLP 
       710        720        730        740        750
KLEVLDLAGN QLKALTNGSL PAGTRLRRLD VSCNSISFVA PGFFSKAKEL 
       760        770        780        790        800
RELNLSANAL KTVDHSWFGP LASALQILDV SANPLHCACG AAFMDFLLEV 
       810        820        830        840        850
QAAVPGLPSR VKCGSPGQLQ GLSIFAQDLR LCLDEALSWD CFALSLLAVA 
       860        870        880        890        900
LGLGVPMLHH LCGWDLWYCF HLCLAWLPWR GRQSGRDEDA LPYDAFVVFD 
       910        920        930        940        950
KTQSAVADWV YNELRGQLEE CRGRWALRLC LEERDWLPGK TLFENLWASV 
       960        970        980        990       1000
YGSRKTLFVL AHTDRVSGLL RASFLLAQQR LLEDRKDVVV LVILSPDGRR 
      1010       1020       1030       1040       1050
SRYVRLRQRL CRQSVLLWPH QPSGQRSFWA QLGMALTRDN HHFYNRNFCQ 

GPTAE                                                  

        10         20         30         40         50
MLYSSCKSRL LDSVEQDFHL EIAKKGFCRS ALHPLSLLVQ AIMLAMTLAL 
        60         70         80         90        100
GTLPAFLPCE LQPHGLVNCN WLFLKSVPHF SMAAPRGNVT SLSLSSNRIH 
       110        120        130        140        150
HLHDSDFAHL PSLRHLNLKW NCPPVGLSPM HFPCHMTIEP STFLAVPTLE 
       160        170        180        190        200
ELNLSYNNIM TVPALPKSLI SLSLSHTNIL MLDSASLAGL HALRFLFMDG 
       210        220        230        240        250
NCYYKNPCRQ ALEVAPGALL GLGNLTHLSL KYNNLTVVPR NLPSSLEYLL 
       260        270        280        290        300
LSYNRIVKLA PEDLANLTAL RVLDVGGNCR RCDHAPNPCM ECPRHFPQLH 
       310        320        330        340        350
PDTFSHLSRL EGLVLKDSSL SWLNASWFRG LGNLRVLDLS ENFLYKCITK 
       360        370        380        390        400
TKAFQGLTQL RKLNLSFNYQ KRVSFAHLSL APSFGSLVAL KELDMHGIFF 
       410        420        430        440        450
RSLDETTLRP LARLPMLQTL RLQMNFINQA QLGIFRAFPG LRYVDLSDNR 
       460        470        480        490        500
ISGASELTAT MGEADGGEKV WLQPGDLAPA PVDTPSSEDF RPNCSTLNFT 
       510        520        530        540        550
LDLSRNNLVT VQPEMFAQLS HLQCLRLSHN CISQAVNGSQ FLPLTGLQVL 
       560        570        580        590        600
DLSHNKLDLY HEHSFTELPR LEALDLSYNS QPFGMQGVGH NFSFVAHLRT 
       610        620        630        640        650
LRHLSLAHNN IHSQVSQQLC STSLRALDFS GNALGHMWAE GDLYLHFFQG 
       660        670        680        690        700
LSGLIWLDLS QNRLHTLLPQ TLRNLPKSLQ VLRLRDNYLA FFKWWSLHFL 
       710        720        730        740        750
PKLEVLDLAG NQLKALTNGS LPAGTRLRRL DVSCNSISFV APGFFSKAKE 
       760        770        780        790        800
LRELNLSANA LKTVDHSWFG PLASALQILD VSANPLHCAC GAAFMDFLLE 
       810        820        830        840        850
VQAAVPGLPS RVKCGSPGQL QGLSIFAQDL RLCLDEALSW DCFALSLLAV 
       860        870        880        890        900
ALGLGVPMLH HLCGWDLWYC FHLCLAWLPW RGRQSGRDED ALPYDAFVVF 
       910        920        930        940        950
DKTQSAVADW VYNELRGQLE ECRGRWALRL CLEERDWLPG KTLFENLWAS 
       960        970        980        990       1000
VYGSRKTLFV LAHTDRVSGL LRASFLLAQQ RLLEDRKDVV VLVILSPDGR 
      1010       1020       1030       1040       1050
RSRYVRLRQR LCRQSVLLWP HQPSGQRSFW AQLGMALTRD NHHFYNRNFC 

QGPTAE                                                 

        10         20         30         40         50
MAIMLAMTLA LGTLPAFLPC ELQPHGLVNC NWLFLKSVPH FSMAAPRGNV 
        60         70         80         90        100
TSLSLSSNRI HHLHDSDFAH LPSLRHLNLK WNCPPVGLSP MHFPCHMTIE 
       110        120        130        140        150
PSTFLAVPTL EELNLSYNNI MTVPALPKSL ISLSLSHTNI LMLDSASLAG 
       160        170        180        190        200
LHALRFLFMD GNCYYKNPCR QALEVAPGAL LGLGNLTHLS LKYNNLTVVP 
       210        220        230        240        250
RNLPSSLEYL LLSYNRIVKL APEDLANLTA LRVLDVGGNC RRCDHAPNPC 
       260        270        280        290        300
MECPRHFPQL HPDTFSHLSR LEGLVLKDSS LSWLNASWFR GLGNLRVLDL 
       310        320        330        340        350
SENFLYKCIT KTKAFQGLTQ LRKLNLSFNY QKRVSFAHLS LAPSFGSLVA 
       360        370        380        390        400
LKELDMHGIF FRSLDETTLR PLARLPMLQT LRLQMNFINQ AQLGIFRAFP 
       410        420        430        440        450
GLRYVDLSDN RISGASELTA TMGEADGGEK VWLQPGDLAP APVDTPSSED 
       460        470        480        490        500
FRPNCSTLNF TLDLSRNNLV TVQPEMFAQL SHLQCLRLSH NCISQAVNGS 
       510        520        530        540        550
QFLPLTGLQV LDLSHNKLDL YHEHSFTELP RLEALDLSYN SQPFGMQGVG 
       560        570        580        590        600
HNFSFVAHLR TLRHLSLAHN NIHSQVSQQL CSTSLRALDF SGNALGHMWA 
       610        620        630        640        650
EGDLYLHFFQ GLSGLIWLDL SQNRLHTLLP QTLRNLPKSL QVLRLRDNYL 
       660        670        680        690        700
AFFKWWSLHF LPKLEVLDLA GNQLKALTNG SLPAGTRLRR LDVSCNSISF 
       710        720        730        740        750
VAPGFFSKAK ELRELNLSAN ALKTVDHSWF GPLASALQIL DVSANPLHCA 
       760        770        780        790        800
CGAAFMDFLL EVQAAVPGLP SRVKCGSPGQ LQGLSIFAQD LRLCLDEALS 
       810        820        830        840        850
WDCFALSLLA VALGLGVPML HHLCGWDLWY CFHLCLAWLP WRGRQSGRDE 
       860        870        880        890        900
DALPYDAFVV FDKTQSAVAD WVYNELRGQL EECRGRWALR LCLEERDWLP 
       910        920        930        940        950
GKTLFENLWA SVYGSRKTLF VLAHTDRVSG LLRASFLLAQ QRLLEDRKDV 
       960        970        980        990       1000
VVLVILSPDG RRSRYVRLRQ RLCRQSVLLW PHQPSGQRSF WAQLGMALTR 
      1010 
DNHHFYNRNF CQGPTAE                                     

Experimental Info

Natural variant

Alternative sequence

Sequence databases

Genome annotation databases

Keywords - Coding sequence diversityⁱ

<p>This section provides links to proteins that are similar to the protein sequence(s) described in this entry at different levels of sequence identity thresholds (100%, 90% and 50%) based on their membership in UniProt Reference Clusters (<a href="http://www.uniprot.org/help/uniref">UniRef</a>).<p><a href='/help/similar_proteins_section' target='_top'>More...</a></p>Similar proteinsⁱ

• 100% Identity
• 90% Identity
• 50% Identity

<p>This section is used to point to information related to entries and found in data collections other than UniProtKB.<p><a href='/help/cross_references_section' target='_top'>More...</a></p>Cross-referencesⁱ

Sequence databases

3D structure databases

Protein-protein interaction databases

Chemistry databases

PTM databases

Polymorphism and mutation databases

Proteomic databases

Protocols and materials databases

Genome annotation databases

Organism-specific databases

Phylogenomic databases

Enzyme and pathway databases

Miscellaneous databases

Gene expression databases

Family and domain databases

<p>This section provides general information on the entry.<p><a href='/help/entry_information_section' target='_top'>More...</a></p>Entry informationⁱ

<p>This section contains any relevant information that doesn’t fit in any other defined sections<p><a href='/help/miscellaneous_section' target='_top'>More...</a></p>Miscellaneousⁱ

Keywords - Technical termⁱ

Documents

1. Human cell differentiation molecules
   CD nomenclature of surface proteins of human leucocytes and list of entries
2. SIMILARITY comments
   Index of protein domains and families
3. Human chromosome 3
   Human chromosome 3: entries, gene names and cross-references to MIM
4. Human polymorphisms and disease mutations
   Index of human polymorphisms and disease mutations
5. MIM cross-references
   Online Mendelian Inheritance in Man (MIM) cross-references in UniProtKB/Swiss-Prot
6. Human entries with polymorphisms or disease mutations
   List of human entries with polymorphisms or disease mutations